Publisher: Research Institute for Gastroenterology and Liver Diseases (RIGLD)
  • Register
  • Login

Gastroenterology and Hepatology from Bed to Bench

  • Home
  • Issues
    • Current
    • Archives
  • About
    • About the Journal
    • Aims and Scope
    • Editorial Team
    • Privacy Statement
    • Contact
  • For Authors
    • Submissions
    • Author Guidelines
    • Peer Review Process
  • Indexing & Abstracting
  • Announcements
Advanced Search
  1. Home
  2. Archives
  3. Vol. 3 No. 2 (2010): Spring
  4. Brief Report

ISSN: 2008-2258

Spring
Vol. 3 No. 2 (2010)

Preliminary report on safety and response rate of pegylated interferon- alpha 2a (pegasys) in genotype D chronic hepatitis B patients in Iran

  • Mostafa Alavi-Moghaddam
  • Seyed-Moayed Alavian
  • Bashir Hajibeigi

Gastroenterology and Hepatology from Bed to Bench, Vol. 3 No. 2 (2010),
https://doi.org/10.22037/ghfbb.v3i2.86 Published 15 March 2010

  • View Article
  • Download
  • Cite
  • Statastics
  • Share

Abstract

Aim: The aim of study was to determine the preliminary result of treatment with pegasys in Iranian chronic hepatitis B patients (with genotype D) referred to Tehran Hepatitis center (THC).

Background: The genotype of HBV and ethnicity of the patients can affect the response rate to pegasys.

Patients and methods: During 2006-2008, 12 Patients with naïve chronic hepatitis B (genotype D) that referred to THC and candidate for treatment were consequently enrolled in this cross sectional study. All of the patients signed the written consent to enter the study. They were treated weekly with 180 microgram of pegylated interferon- alpha 2a (pegasys) subcutaneously. They were visited monthly during their treatment and follow up course in THC. The safety of treatment, the end of treatment response, the relapse rate and the sustained virologic response were measured in these patients.

Results: The end of treatment response rate was 83.3% in total. In patients who had end treatment response, the relapse rate was 50% (4/8) among HBeAg negative patients and 75% (3/4) among HBeAg positive patients. The sustained virologic response rate in this study was 41.6%.

Conclusion: Our study showed that after treatment with pegasys, the genotype D chronic hepatitis B patients had an acceptable sustained virologic response rate (More than 30%). But the influence of HBV genotype on treatment response with pegasys needs to be reevaluated in these patients in future studies. In addition other patient-specific characteristics like genetic aspects should be taken into consideration.
Keywords:
  • Hepatitis B
  • Therapy
  • Pegasys
  • PDF

How to Cite

Alavi-Moghaddam, M., Alavian, S.-M., & Hajibeigi, B. (2010). Preliminary report on safety and response rate of pegylated interferon- alpha 2a (pegasys) in genotype D chronic hepatitis B patients in Iran. Gastroenterology and Hepatology from Bed to Bench, 3(2). https://doi.org/10.22037/ghfbb.v3i2.86
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX
  • Abstract Viewed: 349 times
  • PDF Downloaded: 92 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram
Open Journal Systems
Keywords
Current Issue
  • Atom logo
  • RSS2 logo
  • RSS1 logo
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

GHFBB journal is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

Print ISSN: 2008-2258
Online ISSN: 2008-4234

Support Contact: ghfbb.journal@gmail.com

 

GHFBB is an open-access journal and does not charge fees for authors who submit their articles and for readers who access PDF files of published articles.

The template of this website is designed by Sinaweb